The big news on the opening day of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) was a report about an infant with HIV who started combination antiretroviral treatment very early and now shows no evidence of replication-competent virus. "We equate this to our Berlin Patient," said Deborah Persaud from Johns Hopkins University School of Medicine. "It could get us on the road to a cure for HIV-infected children."
HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
About 10% of gay men in a U.S. study had detectable HIV in their semen despite suppression of blood plasma viral load with antiretroviral therapy (ART), which has implications for HIV transmission, according to a study described in the April 17, 2013, advance online edition of Clinical Infectious Diseases. Having a low but detectable blood viral load and coinfection with cytomegalovirus or Epstein-Barr virus were associated with increased likelihood of semen HIV shedding.
Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after 3 months, according to findings from the PROMISE study presented at the Digestive Disease Week meeting (DDW 2013) this week in Orlando.